PRISM Pharma Co., Ltd. (Prism)

Oncology Corporate Profile

HQ Location

4259-3 Nagatsutacho Midoriku
Yokohama Kanagawa, Japan 226.-8510

Company Description

PRISM focuses on the development of PRI-724 and other lead compounds found from its platform technology and extensive chemical library. Further research on the proprietary protein-protein interaction regulating platform technology and discovery of new lead compounds continues at PRISM Pharma's 100% subsidiary, PRISM BioLab Co., Ltd


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
PRI-724CBP/-catenin inhibitorAcute Myelogenous Leukemia (AML)I
PRI-724CBP/-catenin inhibitorChronic Myelogenous Leukemia (CML)I

View additional information on product candidates here »


Recent News Headlines

There are no news items to display